Liminatus Pharma Disclosed Failure to Satisfy a Continued Listing Rule or Standard

On July 20, 2026, Nasdaq notified the company that it has not regained compliance with Nasdaq Listing Rule 5450(a)(1) (the $1.00 minimum bid price) and is not eligible for a second 180-day extension. The matter is before the Nasdaq Hearings Panel, and the company must submit its written response by July 27, 2026; there is no assurance of additional time or regaining compliance.

Original SEC Filing:

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.